Metrics as of 10/17/2026, 01:50 AM (Berlin time), refresh in progress.
RxSight Stock
RxSight, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Aziz Mottiwala
- Employees
- 461
- Market cap
- $188 M
- IPO
- 30/07/2021
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery,…
RxSight stock: price history
1D
-3.4%
1W
-6.2%
1M
-16.5%
6M
-40.7%
YTD
-56.7%
1Y
-46.8%
2Y
-91.1%
5Y
-66.7%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~20% stronger price swings than usual
Ask the agents about RxSight
Analyst assessment of RxSight
PRICE TARGET LOW
US$5.50
CONSENSUS
US$7.31
MEDIAN
US$6.38
PRICE TARGET HIGH
US$11.00
0
STRONG BUY
3
BUY
7
HOLD
2
SELL
0
STRONG SELL
12
TOTAL · Hold
As of: 22/09/2026
RxSight stock metrics
P/E
-3.99
P/B
0.71
EV/EBITDA
-4.27
RETURN ON EQUITY
-4.6%
NET MARGIN
-35.9%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
92.8%
FLOAT SHARES
38,582,111
AVG. DAILY VOLUME (30D)
777,235
Insider transactions (SEC)
Weinberg Eric
Weinberg Eric
Weinberg Eric
Goldshleger Ilya
Goldshleger Ilya
Institutional holders
Comparable stocks
Frequently asked questions about RxSight stock
What does RxSight do?
RxSight, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Aziz Mottiwala, the company employs around 461 people.
The IPO was on 30/07/2021; the stock trades on NASDAQ under the ticker RXST.
What do analysts say about RxSight stock?
12 analysts rate the stock, the consensus is Hold (as of 22/09/2026).
The average price target is US$7.31, ranging from US$5.50 to US$11.00, with a median of US$6.38.
This is an external assessment, not a statement by Market Jury.
When does RxSight report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 20% stronger than usual.
Does RxSight pay a dividend?
No, RxSight currently does not pay a dividend.
Which stocks are comparable to RxSight?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get RxSight stock analyzed?
Clicking "Analyze stock" lets five strategies assess RxSight against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.